ArticleJournal of translational medicine2004
Tumor antigens for cancer immunotherapy: therapeutic potential of xenogeneic DNA vaccines.
Article in Journal of translational medicine, 2004. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 61 citations in OpenAlex.
- The evolution of cancer immunotherapy: a comprehensive review of its history and current perspectives.Korean journal of clinical oncology · 2024Review
- Public neoantigens in breast cancer immunotherapy (Review).International journal of molecular medicine · 2024Review
- Immunotherapeutic Agents for Intratumoral Immunotherapy.Vaccines · 2023Review
- Anti-tumor activity of intratumoral xenogeneic urothelial cell monotherapy or in combination with chemotherapy in syngeneic murine models of bladder cancer.American journal of cancer research · 2023Article
- Physical and in silico immunopeptidomic profiling of a cancer antigen prostatic acid phosphatase reveals targets enabling TCR isolation.Proceedings of the National Academy of Sciences of the United States of America · 2022Article
- MMP-7 derived peptides with MHC class-I binding motifs from canine mammary tumor tissue elicit strong antigen-specific T-cell responses in BALB/c mice.Molecular and cellular biochemistry · 2021Article
- Immunity to X-linked inhibitor of apoptosis protein (XIAP) in malignant melanoma and check-point blockade.Cancer immunology, immunotherapy : CII · 2019Article
- Combination immunotherapy with Survivin and luteinizing hormone-releasing hormone fusion protein in murine breast cancer model.World journal of clinical oncology · 2018Article
- Prostate cancer health disparities: An immuno-biological perspective.Cancer letters · 2018Article
- HLA-mediated tumor escape mechanisms that may impair immunotherapy clinical outcomes via T-cell activation.Oncology letters · 2017Article
- Applying Subtractive Hybridization Technique to Enrich and Amplify Tumor-Specific Transcripts of Esophageal Squamous Cell Carcinoma.Pathology oncology research : POR · 2017Article
- Sharpening the Edge for Precision Cancer Immunotherapy: Targeting Tumor Antigens through Oncolytic Vaccines.Frontiers in immunology · 2017Review
- Article
- Microenvironment of tumor-draining lymph nodes: opportunities for liposome-based targeted therapy.International journal of molecular sciences · 2014Review
- Mechanism of DNA damage responses induced by exposure to an oligonucleotide homologous to the telomere overhang in melanoma.Oncotarget · 2013Article
- Investigation of DNA integration into reproductive organs following intramuscular injection of DNA in mice.Reports of biochemistry & molecular biology · 2012Article
- Antitumor and anti-angiogenesis immunity induced by CR-SEREX-identified Xenopus RHAMM.Cancer science · 2010Article
- Targeting cancer stem cells in cancer prevention and therapy.Stem cell reviews · 2008Review
- Synergistic anti-tumor effect of recombinant chicken fibroblast growth factor receptor-1-mediated anti-angiogenesis and low-dose gemcitabine in a mouse colon adenocarcinoma model.World journal of gastroenterology · 2007Article
- Anti-angiogeneic target therapy for cancer with vaccine based on the recombinant chicken FGFR-1 in tumor-bearing mice.Journal of Huazhong University of Science and Technology. Medical sciences = Hua zhong ke ji da xue xue bao. Yi xue Ying De wen ban = Huazhong keji daxue xuebao. Yixue Yingdewen ban · 2007Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Preclinical animal studies have convincingly demonstrated that tumor immunity to self antigens can be actively induced and can translate into an effective anti-tumor response. Several of these observations are being tested in clinical trials. Immunization with xenogeneic DNA is an attractive approach to treat cancer since it generates T cell and antibody responses. When working in concert, these mechanisms may improve the efficacy of vaccines. The use of xenogeneic DNA in overcoming immune tolerance has been promising not only in inbred mice with transplanted tumors but also in outbred canines, which present with spontaneous tumors, as in the case of human. Use of this strategy also overcomes limitations seen in other types of cancer vaccines. Immunization against defined tumor antigens using a xenogeneic DNA vaccine is currently being tested in early phase clinical trials for the treatment of melanoma and prostate cancers, with proposed trials for breast cancer and Non-Hodgkin's Lymphoma.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.